X-COR Therapeutics

About:

X-COR Therapeutics is a medical device company creating the first commercially available CO2 removal device.

Website: http://xcortherapeutics.com/

Top Investors: Good Growth Capital, MassChallenge, MedTech Innovator, The Graduate Syndicate, PiSA Biopharm

Description:

X-COR Therapeutics is a Boston based medical device company creating the first commercially available CO2 removal device that uses ultra-low-blood flows for a cheaper, safer, and more accessible treatment for acute respiratory failure. X-COR was the runner-up in the 2018 Harvard President’s Innovation Challenge with its device, a novel consumable hybrid cartridge that removes CO2 from patients’ blood with less invasive procedures than high-flow alternatives. X-COR is part of the 2018 MedTech Innovator and MassChallenge cohorts. X-COR’s core technology is a patent-pending medical device that allows physicians to remove excess CO2 from patients who are in symptomatic lung failure and its accompanying control algorithm that is based on machine-learning techniques. The system is compatible with existing medical device infrastructure for ease of use and deployment. Unlike other technologies to treat lung failure, X-COR uses a hybrid approach that allows patients’ blood to be drawn at <300 ml/min flows through small catheters that can be placed by nursing staff. This therapy is more affordable, safer, and more accessible than existing comparable extracorporeal devices that often require >3 L/min flows and highly specialized physicians.